A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma

A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma

Abstract MYC oncogene rearrangements (MYC-R) negatively affect survival in patients with Ann Arbor stage III–IV diffuse large B-cell lymphoma (DLBCL), but their impact in limited stage (LS) I–II is unclear. Therefore, we assessed the impact of MYC-R on progression-free survival (PFS) and overall sur...

Full description

Bibliographic Details
Main Authors:	A. V. de Jonge, J. A. A. Bult, D. F. E. Karssing, M. Nijland, M. E. D. Chamuleau, M. Brink
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-01-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00971-y

Similar Items

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
by: Mohammad Barouqa, et al.
Published: (2022-08-01)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
by: A. Ortuzar Pasalodos, et al.
Published: (2022-06-01)

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy
by: A. Vera de Jonge, et al.
Published: (2020-10-01)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements, Diffuse Large B-Cell Lymphoma with <i>MYC</i>-Rearrangement, and Diffuse Large B-Cell Lymphoma with <i>MYC</i>-Cluster Amplification
by: Masashi Miyaoka, et al.
Published: (2022-11-01)

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications
by: Dima El-Sharkawi, et al.
Published: (2023-04-01)

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL
by: F. Morschhauser, et al.
Published: (2022-06-01)

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
by: Julum Nwanze, et al.
Published: (2017-09-01)

Diffuse large B-cell lymphoma with concomitant c-MYC and BCL6 gene rearrangements with primary skin involvement: A case report and a review of literature
by: N G Gabeeva, et al.
Published: (2017-07-01)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
by: Weiping Li, et al.
Published: (2019-07-01)

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
by: Alison M. Moore, et al.
Published: (2018-05-01)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
by: A. Vera de Jonge, et al.
Published: (2023-05-01)

Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI)
by: Shadbolt Bruce, et al.
Published: (2009-11-01)

C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies.
by: Kuangguo Zhou, et al.
Published: (2014-01-01)

Anaplastic multiple myeloma with MYC rearrangement
by: Satoshi Ichikawa, et al.
Published: (2022-01-01)

P120: Novel genomic rearrangement leading to MYC over expression in the genomic setting of a pseudo-triple-hit diffuse large B-cell lymphoma
by: Ramakrishna Koduru, et al.
Published: (2024-01-01)

Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning
by: Thomas E. Tavolara, et al.
Published: (2024-01-01)

P1159: INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP
by: Diana Al-Sarayfi, et al.
Published: (2023-08-01)

Differentiated approach in the treatment of diffuse large B-cell lymphoma according to c-MYC and BCL2 status
by: R. K. Karakulov, et al.
Published: (2022-01-01)

High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
by: Thomas S Rogers, et al.
Published: (2019-08-01)

Prognostication of Primary Tumor Location in Early-Stage Nodal Diffuse Large B-Cell Lymphoma: An Analysis of the SEER Database
by: Yi Xia, et al.
Published: (2021-08-01)

Advanced strategies for end-stage heart failure: combining regenerative approaches with LVAD, a new horizon?
by: Cheyenne eTseng, et al.
Published: (2015-04-01)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
by: W. Mo, et al.
Published: (2022-06-01)

Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma
by: Karsten Kleo, et al.
Published: (2019-04-01)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
by: Jonathan Wawire, et al.
Published: (2019-04-01)

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
by: Diana Al-Sarayfi, et al.
Published: (2022-09-01)

MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)
by: Maria Chiara Tisi, et al.
Published: (2019-12-01)

High‐grade B‐cell lymphoma with MYC and BCL2 rearrangements with abundant multinucleated giant tumor cells
by: Man Zhang, et al.
Published: (2023-05-01)

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
by: Johanna A. A. Bult, et al.
Published: (2023-09-01)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
by: Yanjie Wang, et al.
Published: (2023-09-01)

Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation.
by: Haralambieva, E, et al.
Published: (2006)

Limited-stage diffuse large B-cell lymphoma: current management and challenges
by: Zhang, X-Y, et al.
Published: (2021)

The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
by: Lotteke J. Y. M. Ziel-Swier, et al.
Published: (2022-01-01)

Primary Nodal Unclassifiable CD20 Negative Diffuse Large B-cell Lymphoma With Dual and Gene Rearrangement: A Diagnostic Challenge
by: Ita Hadžisejdić, et al.
Published: (2023-01-01)

Identification of MYC/BCL2 double-expressers lymphomas in diffuse large B cell lymphoma patients and association with their prognostic parameters and survival rates: a single centre experience
by: Ahmad, Aliza, et al.
Published: (2022)

A digital method to interpret the C-MYC stain in diffuse large B cell lymphoma
by: Jayalakshmi Balakrishna, et al.
Published: (2022-01-01)

A DIGITAL METHOD TO INTERPRET THE C-MYC STAIN IN DIFFUSE LARGE B CELL LYMPHOMA
by: Jayalakshmi P. Balakrishna, et al.
Published: (2022-01-01)

MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.
by: Kamraan Z Gill, et al.
Published: (2014-01-01)

An artificial intelligence system applied to recurrent cytogenetic aberrations and genetic progression scores predicts MYC rearrangements in large B‐cell lymphoma
by: Rolando García, et al.
Published: (2022-08-01)

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors
by: Pamela B Allen, et al.
Published: (2017-09-01)

A New Staging System Based on the Dynamic Prognostic Nomogram for Elderly Patients With Primary Gastrointestinal Diffuse Large B-Cell Lymphoma
by: Junmin Wang, et al.
Published: (2022-05-01)